Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08), Zacks reports. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The business had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter last year, the firm earned ($0.14) earnings per share. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.
Y-mAbs Therapeutics Trading Up 1.9 %
Shares of NASDAQ:YMAB opened at $12.20 on Thursday. Y-mAbs Therapeutics has a 1 year low of $4.69 and a 1 year high of $20.90. The business has a fifty day simple moving average of $11.84 and a 200 day simple moving average of $13.71. The firm has a market cap of $535.37 million, a price-to-earnings ratio of -24.43 and a beta of 0.66.
Insider Buying and Selling at Y-mAbs Therapeutics
In related news, insider Thomas Gad sold 7,351 shares of Y-mAbs Therapeutics stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Thomas Gad sold 7,351 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now directly owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the transaction, the chief financial officer now directly owns 210,877 shares in the company, valued at $2,545,285.39. The disclosure for this sale can be found here. Insiders have sold a total of 99,444 shares of company stock worth $1,203,925 over the last three months. Corporate insiders own 21.50% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Research Report on YMAB
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Read More
- Five stocks we like better than Y-mAbs Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Why Meta Could Be A $600 Stock Within Weeks
- Most Volatile Stocks, What Investors Need to Know
- Conservative Portfolio: Strategies for Stability
- What is a SEC Filing?
- Unlocking Growth: Why Arcos Dorados Belongs in Your Portfolio
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.